Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | RAF1 | P04049 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.55 |
| ▸ | MERTK | Q12866 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.48 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30310607 | 1.00 | MAPK1 (0.58) | MAPK1TSHRALDH1A1MAPTLMNA | |
| SCHEMBL541479 | 0.85 | ALDH1A1 (0.68) | MAPK1ALDH1A1MAPTLMNARAF1 | |
| SCHEMBL9192519 | 0.85 | MAPK1 (0.62) | MAPK1TSHRALDH1A1MAPTLMNA | |
| SCHEMBL1662886 | 0.82 | ALDH1A1 (0.65) | MAPK1TSHRALDH1A1MAPTMERTK | |
| SCHEMBL30922851 | 0.82 | MAPK1 (0.50) | MAPK1TSHRALDH1A1MAPTLMNA | |
| SCHEMBL11199415 | 0.81 | ALDH1A1 (0.54) | MAPK1ALDH1A1MAPTLMNARAF1 | |
| SCHEMBL10628038 | 0.81 | MAPT (0.67) | MAPK1TSHRALDH1A1MAPTLMNA | |
| SCHEMBL28120167 | 0.81 | MAPK1 (0.53) | MAPK1TSHRALDH1A1MAPTLMNA | |
| SCHEMBL14920998 | 0.80 | MAPK1 (0.56) | MAPK1TSHRALDH1A1MAPTLMNA | |
| SCHEMBL1857266 | 0.80 | MAPK1 (0.51) | MAPK1TSHRALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105859559-A | Production method of 3-ethoxy-4-nitrophenol | 盐城工学院 | 2016-08-17 | — | — | CN | claimed |
| JP-8019095-B2 | — | — | 1996-02-28 | — | — | JP | claimed |
| EP-0302874-B1 | INDOLOQUINONE COMPOUNDS | SPECKAMP, Willem Nico (NL) | 1992-12-02 | — | — | EP | claimed |
| EP-0302874-A1 | INDOLOQUINONE COMPOUNDS. | SPECKAMP WILLEM NICO (NL) | 1989-02-15 | — | — | EP | claimed |
| WO-1987006227-A2 | INDOLOQUINONE COMPOUNDS | JOUHAR AKBAR JAN (GB) | 1987-10-22 | — | — | WO | claimed |
| EP-3741760-B1 | COMPOUNDS, PROCESS FOR OBTAINING THE COMPOUNDS, PHARMACEUTICAL COMPOSITION, USE OF THE COMPOUNDS AND METHOD FOR TREATING PSYCHIATRIC DISORDERS AND/OR SLEEP DISORDERS | ACHE LABORATORIOS FARMACEUTICOS SA (BR) | 2024-12-04 | — | — | EP | disclosed |
| CN-118878470-A | Novel quetiapine analogue, and preparation method and application thereof | 北京安博睿达医药科技有限公司 | 2024-11-01 | — | — | CN | disclosed |
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-13 | — | — | US | disclosed |
| EP-3529234-B1 | COMPOUNDS, PROCESS FOR OBTAINING THE COMPOUNDS, PHARMACEUTICAL COMPOSITION, USE OF THE COMPOUNDS AND METHOD FOR TREATING PSYCHIATRIC DISORDERS AND/OR SLEEP DISORDERS | ACHE LABORATORIOS FARMACEUTICOS SA (BR) | 2023-11-29 | — | — | EP | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| CN-109689647-B | Bicyclic heteroaryl substituted compounds | 百时美施贵宝公司 | 2023-01-20 | — | — | CN | disclosed |
| US-11091445-B2 | Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders | ACHÉ LABORATÓRIOS FARMACÊUTICOS S.A. (BR) | 2021-08-17 | — | — | US | disclosed |
| EP-0039880-B2 | AGENTS FOR THE DETECTION OF ESTEROLYTIC AND/OR PROTEOLYTIC ENZYMES; AND PHENOXY-AMINO ACIDS AND PHENOXY-PEPTIDE ESTERS SUITABLE AS SUBSTRATES THEREFOR, PROCESS FOR THEIR PRODUCTION AND THEIR USE IN PRODUCING THE AGENTS | Roche Diagnostics GmbH (DE) | 1987-06-03 | — | — | EP | disclosed |
| US-4551428-A | COLORIMETRIC ANALYSIS USING DIAZONIUM COUPLERS | BOEHRINGER MANNHEIM GMBH (DE) | 1985-11-05 | — | — | US | disclosed |
| EP-0039880-B1 | AGENTS FOR THE DETECTION OF ESTEROLYTIC AND/OR PROTEOLYTIC ENZYMES; AND PHENOXY-AMINO ACIDS AND PHENOXY-PEPTIDE ESTERS SUITABLE AS SUBSTRATES THEREFOR, PROCESS FOR THEIR PRODUCTION AND THEIR USE IN PRODUCING THE AGENTS | Roche Diagnostics GmbH (DE) | 1983-06-29 | — | — | EP | disclosed |
| US-4369318-A | USING A BENZO-OR PYRIDO-CINNOLINES AS BLEACH CATALYST | CIBA-GEIGY LTD. (CH) | 1983-01-18 | — | — | US | disclosed |
| EP-0017883-B1 | SULPHUR-CONTAINING DIISOCYANATES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS SYNTHESIS COMPONENTS TO PREPARE POLYURETHANES | BAYER AG (DE) | 1981-10-21 | — | — | EP | disclosed |
| US-4266011-A | FUSED PYRIDAZINE CATALYST | CIBA-GEIGY AG (CH) | 1981-05-05 | — | — | US | disclosed |
| EP-0017883-A1 | Sulphur-containing diisocyanates, a process for their preparation and their use as synthesis components to prepare polyurethanes | BAYER AG (DE) | 1980-10-29 | — | — | EP | disclosed |
| US-4020063-A | Oxadiazepine cationic dyestuffs | BAYER AKTIENGESELLSCHAFT (DT) | 1977-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12060347-B2 | Bicyclic heteroaryl substituted compounds | F2, F2RL3, F12 | MAPK1 2622/4885TSHR 1191/4885ALDH1A1 1598/4885 |
| US-11091445-B2 | Compounds, process for obtaining the compounds, pharmaceutical composition, use of the compounds and method for treating psychiatric disorders and/or sleep disorders | MTNR1A, MTNR1B, PER2 | MAPK1 2552/4885TSHR 1001/4885ALDH1A1 293/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | MAPK1 4249/4885TSHR 4669/4885ALDH1A1 1863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.